RenovoRx Assembles Advisory Board to Accelerate TAMP Therapy Commercialization
Event summary
- RenovoRx formed a Medical Advisory Board (MAB) comprised of leading US interventional radiology experts.
- The MAB will focus on clinical insights to advance the TAMP (Trans-Arterial Micro-Perfusion) therapy platform.
- The MAB complements RenovoRx’s existing Scientific Advisory Board.
- RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
- Dr. Ripal Gandhi is leading a post-marketing Registry Study evaluating RenovoCath’s cancer treatment efficacy.
The big picture
RenovoRx's move to establish a dedicated MAB signals a strategic shift towards accelerating commercialization and expanding clinical applications for its RenovoCath device and TAMP therapy platform. This reflects a broader trend in oncology towards localized, targeted therapies to minimize systemic toxicity and improve patient outcomes. The company's reliance on investigator-initiated trials highlights a capital-efficient approach to data generation, but also introduces a degree of uncertainty regarding the pace of clinical validation.
What we're watching
- Clinical Adoption
- The MAB’s influence on investigator-initiated trials will be a key indicator of RenovoCath’s broader adoption within the interventional radiology community.
- Regulatory Pathway
- The FDA’s evaluation of the IAG combination product candidate will determine the timeline and potential for expanded indications and market exclusivity.
- Commercial Traction
- Whether RenovoRx can sustain the momentum from initial purchase orders and repeat orders will be crucial for long-term revenue generation.
Related topics